Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Dyadic sells a gene-expression platform that helps other companies make proteins cheaper and faster.
Dyadic International is a tiny biotech company with a big idea. It owns a protein-making platform called C1, originally borrowed from a heat-loving fungus, that acts like a factory inside a cell. You give it the genetic instructions for a protein, and it churns that protein out quickly and cheaply. Dyadic does not make drugs or sell enzymes to consumers itself. Instead, it licenses this platform to other companies and research groups — pharmaceutical firms, vaccine makers, animal-health companies, and food and industrial-ingredient producers — who pay for access, milestones, and eventually royalties when their products reach the market.
Think of it as the tool-and-die shop of biology: it doesn't build the car, but it supplies the specialized machine that lets others build their car faster and for less money.
The business is small and mostly pre-revenue in a meaningful commercial sense. Annual revenue runs in the low single-digit millions of dollars, and the company has consistently lost money as it spends on research and development to prove the platform works. That is the core tension: Dyadic has a promising, cheap-to-use technology and blue-chip partners, but turning partnerships into recurring product revenue has been slow. Recent focus areas include animal vaccines and proteins, alternative proteins for food, and human therapeutics and vaccines. The upside case rests on landing a partner whose product actually reaches the market, because that is when royalties — the real prize — start flowing. Until then, the company funds itself with cash on hand and occasional equity raises, so watching its cash runway matters more than watching quarterly earnings.
Saved answer · last researched 11 Oct 2026